We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.99B
1-Year Est. Return
737.95%
This Fund
S&P 500
This Quarter
Est. Return
+117.73%
1 Year Est. Return
+737.95%
3 Year Est. Return
+5,256.52%
5 Year Est. Return
+13,483.26%
10 Year Est. Return
+564,575.55%
AUM
$2.51B
AUM Growth
+$863M
(+53%)
Cap. Flow
-$27.8M
Cap. Flow
% of AUM
-1.11%
Top 10 Holdings %
Top 10 Hldgs %
46.81%
Holding
87
New
12
Increased
10
Reduced
29
Closed
20
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
VIE
Viela Bio, Inc. Common Stock
VIE
|
+$37.7M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$31.4M |
| 3 |
Zymeworks
ZYME
|
+$25.4M |
| 4 |
Cabaletta Bio
CABA
|
+$25.1M |
| 5 |
PRNB
Principia Biopharma Inc. Common Stock
PRNB
|
+$24.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$30.6M |
| 2 |
uniQure
QURE
|
+$27.5M |
| 3 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$16.1M |
| 4 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$13.9M |
| 5 |
ALLK
Allakos
ALLK
|
+$12.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 84.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Outlook Therapeutics
OTLK
$187M
| – | – |
-788
| Closed | -$23K |
|
|
SAGE
77
DELISTED
Sage Therapeutics
SAGE
| – | – |
-88,700
| Closed | -$12.4M |
|
78
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$818B
| – | – |
-400,000
| Closed | -$119M |
|
79
Scholar Rock
SRRK
$6.2B
| – | – |
-118,950
| Closed | -$1.06M |
|
80
Q32 Bio
QTTB
$480M
| – | – |
-13,617
| Closed | -$4.44M |
|
|
GTHX
81
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| – | – |
-1,000
| Closed | -$1.02M |
|
|
MRTX
82
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| – | – |
-550,000
| Closed | -$42.9M |
|
|
RUBY
83
DELISTED
Rubius Therapeutics, Inc
RUBY
| – | – |
-491,700
| Closed | -$3.86M |
|
|
PHAS
84
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
| – | – |
-816,448
| Closed | -$3.4M |
|
|
XLRN
85
DELISTED
Acceleron Pharma
XLRN
| – | – |
-25,000
| Closed | -$988K |
|
|
BOLD
86
DELISTED
Audentes Therapeutics, Inc
BOLD
| – | – |
-50,000
| Closed | -$1.41M |
|
|
HSACU
87
DELISTED
Health Sciences Acquisitions Corporation Units
HSACU
| – | – |
-1,080,000
| Closed | -$11.6M |
|
Similar funds
SC
RMCM
RCM
LGM
MYAM
C
TCM
BGM
Cormorant Asset Management's Q4 2019 Portfolio in Review
As of Q4 2019, Cormorant Asset Management held 87 positions worth $2.51B, up 53% from $1.64B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Cormorant Asset Management's Q4 2019 filing shows 12 new, 10 increased, 29 reduced and 20 closed positions. Its largest new stake was Viela Bio, Inc. Common Stock: 1,497,500 shares worth $40.7M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $30.6M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 83% a quarter earlier.
- Cormorant Asset Management's largest Q4 2019 buy was Viela Bio, Inc. Common Stock: 1,497,500 shares worth $40.7M.
- Cormorant Asset Management added most to Constellation Pharmaceuticals, Inc. in Q4 2019, an estimated $31.4M increase.
- Cormorant Asset Management's biggest Q4 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $30.6M.
- Cormorant Asset Management fully exited Sage Therapeutics in Q4 2019, selling an estimated $12.4M.
- Cormorant Asset Management's ten largest holdings make up 47% of its $2.51B portfolio in Q4 2019.
- Cormorant Asset Management opened 12 new positions and closed 20 in Q4 2019.
- Cormorant Asset Management's portfolio value rose 53% quarter-over-quarter to $2.51B.
Based on Cormorant Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.